Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Chromoseq

Research Leaders

20 sponsors active, led by Washington University School of Medicine

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 10 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (3)

Trial Status

Recruiting5
Completed3
Unknown2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (10)

Research Network

Common Treatments

  • Chromoseq2
  • Trained Healthcare Provider1
  • Genetic Counselor1
  • Genetic Study With Nanopore Sequencing1
  • Ultra Rapid Genome Sequencing1

Active Sponsors

  • Washington University School of Medicine2
  • National Human Genome Research Institute (NHGRI)1
  • National Cancer Institute (NCI)1
  • The Second Affiliated Hospital of Chongqing Medical University1
  • HudsonAlpha Institute for Biotechnology1

Top Investigators

Related Conditions

  • Myelodysplastic Syndromes2
  • Cardiomyopathy1
  • Genomic Instability1
  • Nanopore Sequencing1
  • Acute Myeloid Leukemia1

Activity Timeline